The establishment has finally caught up with the marijuana investment trend.
How else to explain a Globe and Mail report that was published Friday under the headline: The pot stock bubble: Inside the rush to profit from medical marijuana.
For all its quality, the Globe is very much the establishment paper and when I worked there a decade ago, business editors didn’t like to sully its reputation by paying much attention to penny stocks.
They preferred to leave it to David Baines (the former Vancouver Sun investigative reporter) and others to wallow in that particular mire.
But at a time when marijuana dispensaries are popping up on every corner in Canadian cities like Vancouver, investor interest in marijuana stocks is something that can’t really be ignored.
And so, Globe business reporter Grant Robertson weighs in with two feature-length articles. The first takes a how we got to here approach, with illuminating comments from Dennis Arsenault, the CEO of
OrganiGram Holdings Inc. (
TSX: V.OGI,
Stock Forum), one of the high profile players in the space.
In a second article that was published on Saturday, Robertson puts the focus on CEN Biotech, a controversial company that aims to become king of Canada's new medical marijuana sector, and even features a short interview with Stockhouse weed expert
Chris Parry.
How we got from there to here is a saga that has been eloquently told on many occasions by Parry.
Like Robertson, he concluded long ago that the Marijuana sector is past the point of being an investment bubble and has now moved on to being a legitimate business, one that (as Robertson correctly points out) has moved the sale of marijuana from the back alley to capital markets.
In Stockhouse this week, Parry puts the spotlight on
T-Bird Pharma (
TSX: V.TPI,
Stock Forum), a Canadian government-licensed MMPR-approved marijuana producer, which may have been blindsided by Health Canada.
Read More
Here are some of the other stories that shocked, appalled, and even thrilled Stockhouse readers this week.
Stockhouse Tech scribe
Gaalen Engen, weighs in with his take on what can only be described as a horrendous week for
Sony (
NYSE: SNE,
Stock Forum) as hackers took both the company and the United States to the cleaners over the planned release of the Seth Rogan and James Franco film,
The Interview.
Hackers, known as the Guardians of Peace or GOP, took offense to the film and on November 24, 2014, notified Sony employees that the company’s network has been breached.
Read More
On yet another investment theme, Dundee Capital Markets has published a comprehensive report on the graphite sector that also flashes buy signals in the direction of
Focus GraphiteInc. (
TSX: V.FMS,
Stock Forum),
Mason Graphite (
TSX: V.LLG,
Stock Forum) and
Energizer Resources (
TSX: T.EGZ,
Stock Forum). It’s worth a look for anyone thinking of investing in graphite stocks.
Read More
Stockhouse client companies making news this week
Anfield Resources Inc. (
TSX: V.ARY,
Stock Forum) continues to focus on generating early-stage cash flow by completing the acquisition of Utah uranium processing facility into production. In doing so, the company is hoping to take advantage of improved market sentiment in the sector and expectations of a sharp increase in the price of uranium.
Read More
Mega Precious Metals Inc. (
TSX: V.MGP,
Stock Forum), a company with an advanced gold-tungsten project in northeastern Manitoba, has been hit hard by tax loss selling in recent weeks.
But the recent decline in the stock price may be an opportunity as the Thunder Bay, Ont., company is ready to press ahead with exploration and development at its flagship Monument Bay Project, which company officials believe has the potential to be a mine.
Read More
Chris Parry offers the view that if investors were looking for a medical cannabis company that wasn’t a flash in the pan, they should look no further than
Bedrocan Cannabis Corp. (
TSX: V.BED,
Stock Forum). But at the same time, this company might be the last one to deliver for traders seeking price spikes and instant returns on investment, Parry writes.
Read More